Surface-engineered nanoparticles in cancer immune response and immunotherapy: Current status and future prospects

• Published in: Biomedicine & pharmacotherapy Vol. 157; p. 113998
• Main Authors: Chen, Jun, Cong, Xiufeng
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.01.2023
• Subjects: Cancer immune response; Cancer immunotherapy; Cancer Vaccines - therapeutic use; Humans; Immunity; Immunotherapy - methods; Nanocarriers; Nanomedicine; Nanoparticles; Neoplasms - therapy; Surface-engineered; Tissue Distribution; TAM; Cancer immune response; PS; SPIONs; BBB; PNPs; MRI; LNPs; MHC; Cancer immunotherapy; LPS; AUC; Nanoparticles; MUC1; GBM; DCs; CLRs; aAPCs; t1/2; O/W; iRGD; HSA; SLNs; MDR; Nanocarriers; MnNPs; APCs; Cmax; NSCLC; Vz; Surface-engineered; MMP2; ASOs; CL; NLCs; PAMAM; VLPs; LNEs; PLGA; PEG; PEI; LESS; PDL1; NK
• ISSN: 0753-3322; 1950-6007; 1950-6007
• DOI: 10.1016/j.biopha.2022.113998

Cancer immunotherapy is a therapeutic strategy to inhibit tumor growth and metastasis by intervening in the immune response process. Strategies applied to cancer immunotherapy mainly include blocking immune checkpoints, adoptive transfer of engineered immune cells, cytokine therapy, cancer vaccines, and oncolytic virus infection. However, many factors, such as off-target side effects, immunosuppressive cell infiltration and/or upregulation of immune checkpoint expression, cancer cell heterogeneity, and lack of antigen presentation, affect the therapeutic effect of immunotherapy on cancer. To improve the efficacy of targeted immunotherapy and reduce off-target effects, over the past two decades, nanoparticle delivery platforms have been increasingly used in tumor immunotherapy. However, nanoparticles are still subject to biological barriers and biodistribution challenges, which limit their overall clinical potential. This has prompted a series of engineered nanoparticles to overcome specific obstacles and transfer the accumulation of payloads to tumor-infiltrating immune cells. In recent years, new techniques and chemical methods have been employed to modify or functionalize the surfaces of nanoparticles. This review discusses the recent progress of surface-engineered nanoparticles in inducing tumor immune responses and immunotherapy, as well as future directions for the development of next-generation nanomedicines. [Display omitted] •Types and biological properties of nanoparticle delivery platforms.•Surface-engineering strategies for enhancing immune cell targeting and immunostimulatory.•Surface-engineered nanoparticles in cancer immune modulation.•Surface-engineered nanoparticles in cancer immunotherapy.